PASG250117P7500
- 0.00
- 0.000.00%
Passage Bio Newsroom
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
Passage Bio Price Target Maintained With a $7.00/Share by Chardan Capital
Passage Bio Is Maintained at Buy by Chardan Capital
Passage Bio Analyst Ratings
Passage Bio's Strong Financial Position and Clinical Progress Justify Buy Rating
TD Cowen Maintains Passage Bio(PASG.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Passage Bio (PASG)
Optimistic Buy Rating for Passage Bio as PBFT02 Shows Promising Results and Market Potential
Rodman & Renshaw Initiates Passage Bio(PASG.US) With Buy Rating, Announces Target Price $7
Buy Rating Affirmed for Passage Bio on Strong Cost Control and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)
Positive Outlook for Passage Bio: Strategic Financial Moves and Promising Clinical Prospects Boost Buy Rating
Expanding Market and Promising Preclinical Results Bolster Buy Rating for Passage Bio
Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating
Canadian Investment Banking Group: Maintaining the Passage Bio (PASG.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $14.00 to $13.00.
Passage Bio Analyst Ratings
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13
Optimistic Outlook for Passage Bio Amid Clinical and Financial Progress: Maintains Buy Rating
Passage Bio (PASG) Gets a Buy From TD Cowen
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)